Delayed elimination of methotrexate after high-dose infusion

Невожай Д.В., Будзынская Р., Каньская У. и др. Современные представления о механизме противоопухолевого действия метотрексата и устойчивости к нему // Тихоокеан. мед. журн. — 2006. — № 4. — С. 12-16.

Пименова М.А., Соколов А.Н., Бирюкова Л.С. и др. Экстремально высокая концентрация метотрексата в сыворотке крови, сопровождавшаяся острой почечной недостаточностью у больного острым лимфобластным лейкозом после высокодозной консолидации // Тер. арх. — 2011. — № 7. — С. 58-61.

Al-Turkmani M.R., Law T., Narla A., Kellogg M.D. Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity // Clin. Chemistry. — 2010. — Vol. 56. — № 12. — P. 1792-1796.

Bremnes R.M., Slordal L., Wist E. et al. Formation and elimination of 7-hydroxymethotrexate in the rat in vivo after methotrexate administration // Cancer Res. — 1989. — Vol. 49. — P. 2460-2464.

Crews K.R., Liu T., Rodriguez-Galindo C. et al. Highdose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma // Cancer (Philad). — 2004. — Vol. 100. — P. 1724-1733.

Ferreri A.J.M., Guerra E., Regazzi M. et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNs lymphomas // Brit. J. Cancer. — 2004. — Vol. 90. — P. 353-358.

Ikeda H., Kihira K., Kuwata N. et al. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy // Hiroshima J. Med. Sci. — 1996. — Vol. 45. — № 2. — P. 57-62.

Joerger M., Huitema A.D.R., van den Bongard H.J.G.D. et al. Determitants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients // Brit. J. Cin. Pharmacol. — 2005. — Vol. 62. — P. 71-80.

Joerger M., Huitema A.D.R., Krähenbühl S. et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial // Brit. J. Cancer. — 2010. — Vol. 102. — P. 673-677.

Lee K.M., Lee H.W., Kim S.Y. et al. Two pediatric osteosarcoma cases with delayed methotrexate excretion: its clinical course and management // Cancer Res. Treat. — 2011. — Vol. 43. — P. 67-70.

Mashhadi M.A., Kaykhaei M.A., Sanadgol H. Low prevalence of high-dose methotrexate nephropathy in patients with malignancy // IJKD. — 2012. — Vol. 6. — P. 105-109.

Sowers R., Wenzel B.D., Richardson C. et al. Impairment of methotrexate transport is common in osteosarcoma tumor samples // Sarcoma. — 2011. — ID 834170.

Treon S.P., Chabner B.A. Concepts in use of high-dose methotrexate therapy // Clin. Chemistry. — 1996. — Vol. 42. — P. 1322-1329.

Vlaming M.L.H., van Esch A., Pala Z. et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo // Mol. Cancer Ther. — 2009. — Vol. 8. — P. 3350-3359.

Widemann B.C., Adamson P.C. Understanding and managing methotrexate nephrotoxicity // Oncologist. — 2006. — Vol. 11. — P. 694-703.

Widemann B.C., Balis F.M., Kim A. et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome // J. Clin. Oncol. — 2010. — Vol. 28. — P. 3979-3986.

Widemann B.C., Sung E., Anderson L. et al. Pharmacokinetics and metabolism of the methotrexate metabolite 2,4-diamino-N10-methylpteroic acid // JPED. — 2000. — Vol. 294. — P. 894-901.